Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase
Authors' conclusion
Baseline HOMA-IR predicted ΔHOMA-IR, with a greater percentage change in insulin than in fasting glucose. In men with MetS/type 2 diabetes (T2DM) not on antiglycaemic therapy, improvements in HOMA-IR may be greater than suggested by change in fasting glucose. Our results suggest that hypogonadism screening be included in the management of men with MetS/T2DM.
Study context
- Population
- Men with metabolic syndrome and hypogonadism; analysis focused on men not receiving antiglycaemic agents (TU: 81; placebo: 54)randomized
- Participants
- 184 men
- Comparison
- Testosterone undecanoate vs placebo
- TUn = 113
- Placebon = 71reference
- Primary endpoint
- Change in HOMA-IR
Methodological detailsplacebo-controlled, double-blind, open-label phase with TU for all
- Placebo-controlled
- Double-blind
- Open-label phase with TU for all
Primary result
As reported in the abstract
Median HOMA-IR vs baseline · almost every time point after 18 weeks
- Median HOMA-IR significantly reduced vs baseline with TU in both study and confirmatory cohorts
- Placebo not associated with significant ∆HOMA-IR
Further findings
Median fasting glucose change after TU
- 30 weeks
- −2.1%
- 138 weeks
- −4.9%
- Significant decrease
Median insulin change after TU
- 30 weeks
- −10.5%
- 138 weeks
- −35.5%
- Significant decrease
Predictors of HOMA-IR decrease after TU
- Only consistent predictor: baseline HOMA-IR (r2)
- ≥ 0.64
Original publication
Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase. Diabetes Obes Metab. Published 3 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →